Get 20% Free Customization In This Report

Buy this report from - $3456

Global Sleep Disorder Treatment Drugs Market by Sleep Disorder (Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, and Sleep Walking), Product (Mattresses and Pillows, Sleep Laboratories, Medications, and Sleep Apnea Devices), and Medication (Prescription-based Drugs, OTC Drugs, and Herbal Drugs) - Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI_184190	Pages: NA	Jun 2018 \| 471 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Sleep disorder or insomnia is a medical disorder in which the patient has difficulty with sleep maintenance or sleep initiation. This disorder causes irregular mental, physical, social, and emotional functions.

Factors such as increasing incidences of depression & other medical disorders, late night working schedule, busy lifestyle, lack of quality sleep, and rising geriatric population drive the market growth. However, patent expirations of major sleep disorder treatment drugs and side effects associated with these drugs such as restlessness & nausea restrain the market growth. Moreover, introduction of home sleep test kits and utilization of wearable monitors & continuous positive airway pressure (CPAP) therapy increase opportunities for the market growth.

The sleep disorder treatment drugs market is segmented on the basis of sleep disorder, product, medication, and region. On the basis of sleep disorder, it is segmented into insomnia, sleep apnea, restless legs syndrome, narcolepsy, and sleep walking. On the basis of product, it is segmented into mattresses & pillows, sleep laboratories, medications, and sleep apnea devices. On the basis of medication, it is segmented into prescription-based drugs, OTC drugs, and herbal drugs. Geographically, the market has been analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players in the market include Pfizer Inc, Sanofi, Merck & Co Inc, GlaxoSmithKline plc, Koninklijke Philips N.V., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cardinal Health, Becton Dickson and Company, and Natus Medical Incorporated.

Key Benefits

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate imminent investment pockets.
It offers a quantitative analysis from 2016 to 2023, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
Extensive analysis by product helps understand various types of products used for sleep disorder treatment.
Comprehensive analysis of all geographical regions has been provided, which helps determine prevailing opportunities.
Key players have been profiled and their strategies thoroughly analyzed, which helps understand the competitive outlook of the global market.

Global Sleep Disorder Treatment Drugs Market Key Segments:

By Sleep Disorder

Insomnia
Sleep Apnea
Restless Legs Syndrome
Narcolepsy
Sleep Walking

By Product

Mattresses and Pillows
Sleep Laboratories
Medications
Sleep Apnea Devices

By Medication

Prescription-based Drugs
OTC Drugs
Herbal Drugs

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GLOBAL SLEEP DISORDER TREATMENT DRUGS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MATTRESSES AND PILLOWS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. SLEEP LABORATORIES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. MEDICATIONS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. SLEEP APNEA DEVICES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

Chapter: 5 GLOBAL SLEEP DISORDER TREATMENT DRUGS MARKET, BY SLEEP DISORDER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. INSOMNIA

5.2.1. Market size and forecast

5.3. SLEEP APNEA

5.3.1. Market size and forecast

5.4. RESTLESS LEGS SYNDROME

5.4.1. Market size and forecast

5.5. NARCOLEPSY

5.5.1. Market size and forecast

5.6. SLEEP WALKING

5.6.1. Market size and forecast

Chapter: 6 GLOBAL SLEEP DISORDER TREATMENT DRUGS MARKET, BY MEDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. PRESCRIPTION-BASED DRUGS

6.2.1. Market size and forecast

6.3. OTC DRUGS

6.3.1. Market size and forecast

6.4. HERBAL DRUGS

6.4.1. Market size and forecast

Chapter: 7 GLOBAL SLEEP DISORDER TREATMENT DRUGS MARKET, BY REGION

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America Sleep Disorder Treatment Drugs Market, by Sleep Disorder
7.2.5. North America Sleep Disorder Treatment Drugs Market, by Product
7.2.6. North America Sleep Disorder Treatment Drugs Market, by Medication

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. Europe Sleep Disorder Treatment Drugs Market, by Sleep Disorder
7.3.5. Europe Sleep Disorder Treatment Drugs Market, by Product
7.3.6. Europe Sleep Disorder Treatment Drugs Market, by Medication

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-Pacific Sleep Disorder Treatment Drugs Market, by Sleep Disorder
7.4.5. Asia-Pacific Sleep Disorder Treatment Drugs Market, by Product
7.4.6. Asia-Pacific Sleep Disorder Treatment Drugs Market, by Medication

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Saudi Arabia market size and forecast
7.5.3.3. South Africa market size and forecast
7.5.3.4. Rest of LAMEA market size and forecast

7.5.4. LAMEA Sleep Disorder Treatment Drugs Market, by Sleep Disorder
7.5.5. LAMEA Sleep Disorder Treatment Drugs Market, by Product
7.5.6. LAMEA Sleep Disorder Treatment Drugs Market, by Medication

Chapter: 8 COMPANY PROFILES

8.1. PFIZER INC

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. SANOFI

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. GLAXOSMITHKLINE PLC _

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. MERCK & CO INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. KONINKLIJKE PHILIPS N.V.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. TAKEDA PHARMACEUTICAL COMPANY LIMITED

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. CARDINAL HEALTH

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. BECTON DICKSON AND COMPANY

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. NATUS MEDICAL INCORPORATED

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.